Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704 Academic Article uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • Double hit lymphoma (DHL) and double protein-expressing (MYC, BCL2) lymphomas (DPL) fare poorly with R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisolone); consolidative autologous stem cell transplant (ASCT) may improve outcomes. S9704, a phase III randomized study of CHOP +/-R with or without ASCT enabled evaluation of intensive consolidation. Immunohistochemistry (IHC) identified 27 of 198 patients (13·6%) with MYC overexpression; 20 (74%) harboured concurrent BCL2 overexpression. Four had DHL and 16 had DPL only. With median 127 months follow-up, there is a trend favouring outcomes after ASCT in DPL and MYC protein overexpressing patients, whereas all DHL patients have died irrespective of ASCT.


  • Puvvada, Soham D
  • Stiff, Patrick J
  • Leblanc, Michael
  • Cook, James R
  • Couban, Stephen
  • Leonard, John P
  • Kahl, Brad
  • Marcellus, Deborah
  • Shea, Thomas C
  • Winter, Jane N
  • Li, Hongli
  • Rimsza, Lisa M
  • Friedberg, Jonathan W
  • Smith, Sonali M

publication date

  • September 2016

has subject area